M&As this week: Aurora Diagnostics, Caesarea Medical Electronics, Innocoll Holdings

6 April 2017 (Last Updated April 6th, 2017 18:30)

Aurora Diagnostics has completed the acquisition of University Pathologists, a provider of hospital-based professional anatomic pathology services in the US, along with its affiliated technical lab, University Pathologists Diagnostics.

Aurora Diagnostics has completed the acquisition of University Pathologists, a provider of hospital-based professional anatomic pathology services in the US, along with its affiliated technical lab, University Pathologists Diagnostics.

The acquisition enables the lab management services provider to expand capabilities to better serve physicians in the hospital laboratory sector.

American medical technology company, Becton, Dickinson and Company (BD) has announced the 100% acquisition of Israel-based infusion pump systems manufacturer, Caesarea Medical Electronics (CME).

The transaction follows BD's acquisition of CareFusion, which owns a 40% non-controlling stake in CME, in 2015. By acquiring the remaining stake in CME, BD intends to expand its infusion portfolio with ambulatory, home and specialty acute care infusion pumps.

Healthcare investment fund company, Gurnet Point, has agreed to acquire pharmaceutical and medical device company, Innocoll Holdings, for a cash consideration of $209m.

"The acquisition is part of Gurnet’s business strategy to invest in life science, medical technology and healthcare service companies."

Pursuant to the agreement, the acquirer will also provide a $10m loan for Innocoll's continued development of XARACOLL, its late-stage surgically implantable product candidate for the treatment of postsurgical pain.

The acquisition is part of Gurnet’s business strategy to invest in life science, medical technology and healthcare service companies.

In a definitive agreement signed between aesthetic medical products developer, Syneron Medical, and Apax Partners, all the outstanding shares of the former will be purchased by an affiliate of funds advised by the latter, for a cash consideration of $397m.

Barclays and J.P. Morgan are the exclusive financial advisors for the acquirer and the target company respectively.